Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study
Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study
复制标题
DOI：
10.1080/09273948.2022.2092007
复制
发表时间：
2022-06-25
影响因子：
3.3
通讯作者：
Herbort, Carl P., Jr.
中科院分区：
文献类型：
--
作者：
Nakai, Shunsaku;Takeuchi, Masaru;Herbort, Carl P., Jr.
目的研究阿达木单抗（ADA）治疗Vogt-Koyanagi-Harada （VKH）患者加重或复发的有效性和安全性。方法对70例接受ADA治疗6个月以上的VKH患者的病历进行回顾性分析。结果VKH患者平均年龄54.8±15.1岁，男女比例34/36，晚霞眼底占71.4%。与基线相比，ADA治疗6个月后，中央凹下脉管炎厚度、吲哚菁绿血管造影评分、皮质类固醇和环孢素剂量显著降低，而LogMAR和flare计数也有所改善，但无统计学意义。不良事件发生率为17.1%，其中结核为7.14%，牛皮癣为2.86%；然而，91.4%的患者继续接受ADA治疗。结论ADA可有效缓解常规治疗难治性VKH疾病，且耐受性良好，很少发生严重不良事件。
Purpose We investigated efficacy and safety of adalimumab (ADA) treatment for exacerbation or recurrence of Vogt-Koyanagi-Harada (VKH) patients. Methods Medical records of 70 VKH patients who received ADA treatment for more than 6 months were retrospectively investigated. Results The mean age of VKH patients was 54.8 +/- 15.1 years, and male/female ratio was 34/36, and sunset glow fundus was observed in 71.4%. Subfoveal choroidal thickness, indocyanine green angiography scores, and corticosteroid and cyclosporine doses were significantly reduced by ADA treatment for 6 months compared to baseline, while LogMAR and flare counts were also improved without being statistically significant. Adverse events were observed in 17.1%, in which tuberculosis was at 7.14% and psoriasis was at 2.86%; however, ADA treatment was continued in 91.4%. Conclusions ADA was shown to be effective to achieve remission of VKH disease refractory to conventional treatments and was generally well tolerated with few serious adverse events.